Variable Endokrinoloji / Adrenal

Cushing Syndrome — Diagnosis, Screening, and Post-Treatment Management

The FIRST QUESTION to ask in Cushing syndrome is not where the hormone comes from, but whether the PATIENT IS TAKING CORTISONE EXTERNALLY; because the MOST COMMON CAUSE is the medication GIVEN BY THE PHYSICIAN. This question remains incomplete if asked only about pills:

INTRA-ARTICULAR injections, creams applied to the SKIN, INHALATION and NASAL sprays can also create the same picture, and patients do not mention them because they do not CONSIDER THEM AS MEDICATION. A SPECIAL TRAP is that a patient using low-dose inhaled corticosteroid may develop a pronounced Cushing's picture when a drug that SUPPRESSES THE DESTRUCTIVE ENZYME IN THE LIVER (some antifungal and antiviral drugs) is added.

Once external intake is ruled out, SCREENING is performed; however, the most common mistake here is not knowing that conditions like ALCOHOL USE, DEPRESSION, UNCONTROLLED DIABETES, and SEVERE OBESITY can cause FALSE POSITIVE SCREENING TESTS. THERE IS A CRUCIAL POINT AFTER TREATMENT: when the disease is successfully eliminated, the body's own production remains SUPPRESSED FOR A LONG TIME; therefore, the patient requires corticosteroid support and ADRENAL INSUFFICIENCY TRAINING for MONTHS, sometimes YEARS.

Additionally, in these patients, the RISK OF BLOOD CLOTTING IS MARKEDLY INCREASED.

Rapid management

FIRST QUESTION:
IS THE PATIENT TAKING CORTISONE EXTERNALLY?
THE MOST COMMON REASON IS MEDICATION PRESCRIBED BY A DOCTOR.
THE QUESTION IS INCOMPLETE IF ASKED ONLY AS A PILL — INTRA-ARTICULAR injections, creams applied to the SKIN, RESPIRATORY and NASAL sprays also create the same pattern; patients do not consider these as MEDICATION.
SPECIAL TRAP:
When a patient using low-dose respiratory cortisone is given a drug that SUPPRESSES THE LIVER BREAKDOWN ENZYME (some ANTIFUNGAL and ANTIVIRAL drugs), the drug ACCUMULATES in the body and a DISTINCT CUSHING syndrome appears.
IF EXTERNAL USE IS EXCLUDED, SCREENING: there are multiple test options and DIAGNOSIS CANNOT BE MADE WITH A SINGLE TEST; usually, ABNORMAL RESULTS IN TWO DIFFERENT TESTS are sought.
CONDITIONS THAT CAUSE FALSE POSITIVE (so-called Cushing):
ALCOHOL USE, DEPRESSION and other psychiatric conditions, UNCONTROLLED DIABETES, SEVERE OBESITY, PREGNANCY, DRUGS CONTAINING ESTROGEN, IRREGULAR SLEEP/SHIFT WORK.
DISTINGUISHING CLINICAL FINDINGS (unexpected in obesity): trunk obesity with MUSCLE WASTING in ARMS and LEGS, WIDE and PURPLE STRIAE, EASY BRUISING, THINNING OF THE SKIN, GROWTH FAILURE + WEIGHT GAIN in CHILDREN.
THE CONDITION MAY BE PERIODIC; a single normal test does not exclude it, REPETITION may be needed.
ONCE DIAGNOSIS IS CONFIRMED, the source is investigated.
COMPLICATIONS:
HIGH BLOOD SUGAR, BLOOD PRESSURE, OSTEOPOROSIS, TENDENCY TO INFECTION, PSYCHIATRIC findings, and SIGNIFICANT RISK OF CLOTS.
POST-TREATMENT KEY POINT: when the disease is resolved, THE BODY'S OWN PRODUCTION REMAINS SUPPRESSED FOR A LONG TIME → the patient may require cortisone support and ADRENAL INSUFFICIENCY TRAINING (disease-day rules, injection, card) for MONTHS, sometimes YEARS.
ALL DOSES and THRESHOLDS MUST BE VERIFIED FROM INSTITUTIONAL PROTOCOL.

Drug	Adult	Pediatric	Route	Duration
FIRST STEP — inquiring about all forms of external cortisone intake When Cushing's syndrome is mentioned, a hormone-producing tumor comes to mind; however, in everyday practice, the most common cause of this condition is corticosteroid-type drugs given by physicians. This distinction changes the entire diagnostic process because if intake is external, hormone tests can be misleading and unnecessary imaging may be performed. It is critical that the inquiry is comprehensive. When patients are asked whether they use corticosteroids, most only think of oral pills and answer negatively. However, injections into the joints, creams applied over a large area for a long time, sprays used for asthma and allergic rhinitis, eye drops, and products administered rectally can create the same condition when absorbed in sufficient amounts. The common feature of these products is that they are not considered medications by the patients; a joint injection is perceived as a procedure, a cream as a care product, and a spray as a habitual daily application. For this reason, the question should not be asked in a general form, but by listing the routes of administration one by one.	In a Cushing syndrome case, EXTERNAL CORTISONE INTAKE should be queried FIRST; this is THE MOST COMMON CAUSE. The question should cover ALL FORMS: PILL, INJECTION, INTRA-ARTICULAR injection, CREAMS AND OINTMENTS applied to the SKIN, RESPIRATORY and NASAL SPRAYS, eye drops, and those used rectally. Herbal and over-the-counter products should also be asked about.	In children, particularly skin creams and respiratory medications should be questioned; the combination of growth arrest and weight gain should be a warning.	—	At the first assessment
SPECIAL PITFALL — the condition arising from enzyme-inhibiting drug This table is one of the most instructive examples demonstrating how drug interactions translate into clinical outcomes, and when unknown, the diagnosis is highly unlikely to be made. The safety of corticosteroids used via the respiratory tract or nasal route relies on the rapidly broken down amount in the liver; therefore, under normal conditions, they do not produce systemic effects. However, this breakdown is carried out by a specific enzyme system, and there are drugs that strongly inhibit this system; some antifungal drugs and some antiviral drugs are at the top of this list. When one of these drugs is added, the corticosteroid can no longer be rapidly broken down, accumulates in the blood, and begins to exert effects throughout the body. The result is the onset of a noticeable Cushing’s syndrome within weeks in a patient who has been using a drug considered safe at a low dose for years. What complicates the recognition of this condition is that the patient’s corticosteroid dose has not changed; therefore, the connection is not made, and the patient is examined for a tumor producing hormones.	In a patient using LOW-DOSE corticosteroids (especially via the RESPIRATORY ROUTE), when a drug that SUPPRESSES THE BREAKDOWN ENZYME in the liver is added, the corticosteroid ACCUMULATES IN THE BODY and a DISTINCT CUSHING SYNDROME emerges. This interaction is particularly observed with certain ANTIFUNGAL and ANTIVIRAL drugs. Newly started drugs should be reviewed in this regard; the interaction list should be VERIFIED FROM THE INSTITUTIONAL PROTOCOL.	The same interaction occurs in children and its impact on growth is significant.	—	Throughout the use of the drug
Situations where screening tests can produce false positives The most common difficulty encountered in the screening for Cushing's syndrome is that cortisol production can also increase due to reasons other than actual disease. The body increases cortisol production in response to ongoing stress; this increase is not disease, but a result of the normal functioning of the system. Alcohol use, depression and anxiety disorders, uncontrolled diabetes, severe obesity, pregnancy, and irregular sleep patterns are such conditions. In these patients, screening tests may appear abnormal and the picture may not be distinguishable from true Cushing's syndrome. Therefore, the presence of these conditions should be questioned before screening, and if possible, the test should be performed after they are corrected; for example, results obtained while alcohol is being used or while diabetes is uncontrolled are not reliable. The second principle is that the diagnosis should not be based on a single test. There are several tests that can be used, each with its own limitations; therefore, usually, abnormality in two different tests is sought, and if the results are inconsistent, the evaluation is repeated.	Situations that can lead to FALSE POSITIVE results should be evaluated before screening: ALCOHOL USE, DEPRESSION and other psychiatric conditions, UNCONTROLLED DIABETES, ADVANCED OBESITY, PREGNANCY, MEDICATIONS CONTAINING ESTROGEN, and IRREGULAR SLEEP PATTERNS. DIAGNOSIS IS NOT MADE WITH A SINGLE TEST; the abnormality is usually sought in TWO DIFFERENT TESTS. Test selection and thresholds must be VERIFIED BY THE INSTITUTIONAL PROTOCOL	Test selection and interpretation in children are done in collaboration with pediatric endocrinology	Laboratory	During the diagnostic process
Searching for distinguishing clinical findings Most of the findings of Cushing's syndrome are common on their own; weight gain, fatigue, high blood pressure, high blood sugar, and mood changes are already expected findings in an obese patient. Therefore, what leads to the diagnosis is not the presence of these findings, but the coexistence of findings unexpected in obesity. The most prominent of these is muscle wasting; excess cortisol breaks down muscle tissue, leading to thinning in the arms and legs, whereas fat accumulation increases in the trunk, face, and neck area. The presence of these two findings together in the same patient cannot be explained by simple obesity. Skin changes are also distinctive; cortisol thins the connective tissue under the skin, resulting in wide, purple stretch marks, easy bruising from minor trauma, and slow healing of wounds. In children, the strongest clue is the growth curve; excess cortisol suppresses height growth while increasing weight gain, so in a child whose height has stopped growing but continues to gain weight, this diagnosis should be primarily considered.	In obesity, UNEXPECTED findings should be sought: MUSCLE WASTING in the ARMS and LEGS along with TRUNK OBESITY, WIDE and PURPLE STRIAE, EASY BRUISING, THINNING OF THE SKIN, DELAYED WOUND HEALING, ROUNDING and REDDENING OF THE FACE. In children, growth cessation along with WEIGHT GAIN is a strong warning and should be prioritized for evaluation	The growth curve in children should definitely be examined; the combination of halted height growth with weight gain is typical	—	On examination
Knowing the course of periodicity and repeated evaluation In a portion of Cushing's syndrome, hormone production is not constant but intermittent; increases in production appear in phases and levels may return to normal in between. This feature complicates the diagnostic process because if the patient's test coincides with a normal period, the results are entirely normal and the diagnosis is ruled out. However, the patient's clinical findings persist and their symptoms fluctuate over time. The practical implication of this situation is as follows: if clinical suspicion is strong, a single normal test result is not sufficient to exclude the diagnosis. Repetition of evaluation during periods when the patient's symptoms increase is necessary to establish the diagnosis. This information is also important for the patient; patients whose tests are normal but continue to have symptoms often think that their complaints are not taken seriously and leave follow-up. Therefore, the reason for repeating the test should be explained to the patient, and when they should present should be outlined.	This picture may be PERIODIC; since hormone production can increase and decrease INTERMITTENTLY, A SINGLE NORMAL TEST DOES NOT RULE OUT THE DIAGNOSIS. If clinical suspicion persists, evaluation MUST BE REPEATED. The timing and method of repetition SHOULD BE VERIFIED FROM THE INSTITUTIONAL PROTOCOL	In children, repeated evaluation may also be required, and growth monitoring continues	Laboratory	As long as suspicion persists
Addressing complications and the risk of clotting Since excess cortisol in Cushing's syndrome affects almost all systems, the management of complications should not be delayed while the diagnostic process is ongoing. High blood sugar and high blood pressure are common and require treatment on their own. Bone density rapidly decreases under the influence of cortisol; this loss can be evident even in young patients and creates a risk of fracture. Because the immune response is suppressed, infections occur more frequently and severely, and diagnostic delay may occur since warning signs such as fever can be muted. Muscle weakness is especially pronounced in the thigh muscles, and difficulty rising from a seated position is a typical finding. Psychiatric effects are often underestimated; insomnia, restlessness, mood swings, and depressive symptoms significantly impair quality of life. However, clinically the most critical complication is the tendency to clot; these patients have a significantly increased risk of intravascular clotting, and this risk becomes particularly important during surgical procedures and periods of immobility.	Complications should also be managed during and after the diagnostic process: HIGH BLOOD SUGAR, HIGH BLOOD PRESSURE, OSTEOPOROSIS, TENDENCY TO INFECTION, PSYCHIATRIC findings, and MUSCLE WEAKNESS. THE RISK OF BLOOD CLOTTING IS SIGNIFICANTLY INCREASED; prevention during surgery and periods of immobility should also be evaluated	Growth, bone health, and school performance in the child should also be monitored	—	During the diagnosis and treatment process
LIFE-THREATENING — long-term adrenal insufficiency after treatment The most frequently overlooked phase in the treatment of Cushing's syndrome is the period after the disease has been eliminated, and this period is of vital importance. In a body exposed to high cortisol levels for a long time, the pituitary's stimulation production and the healthy adrenal gland tissue are suppressed. When the source of the disease is removed, the cortisol level drops rapidly, but the suppressed system cannot start functioning immediately; recovery takes months, sometimes years. During this interim period, the patient functionally experiences adrenal insufficiency and cannot survive without external support. Therefore, these patients should receive all the education given to patients with adrenal insufficiency; the dose should be increased on sick days, intramuscular injection should be administered in case of vomiting, and a warning card to be carried should be provided. The second important issue is that the patient feels unwell during this transition period; the body, accustomed to high cortisol for years, experiences fatigue, muscle and joint pain, loss of appetite, and low mood as it returns to normal. This picture is not a treatment failure, and if not explained to the patient beforehand, they may think the treatment did not work.	When the disease is successfully resolved, THE BODY'S OWN PRODUCTION REMAINS SUPPRESSED FOR A LONG TIME; the patient may need GLUCOCORTICOID SUPPORT for MONTHS, sometimes YEARS. These patients should receive ADRENAL INSUFFICIENCY EDUCATION: SICK DAY RULES, INJECTION APPLICATION DURING VOMITING, and PORTABLE ALERT CARD. The tapering plan should be VERIFIED FROM INSTITUTIONAL PROTOCOL	In children, tapering and growth monitoring is conducted with pediatric endocrinology	Oral	Months, sometimes years

Alternative

Intake of corticosteroids from outside is the most common cause and cannot be excluded without investigating all routes of administration.
Pseudo-Cushing presentations (alcohol, depression, uncontrolled diabetes, severe obesity) cause screening tests to be falsely positive.
Metabolic syndrome and obesity create a similar appearance but there is no muscle wasting or purple striae.
Polycystic ovary syndrome can be confused with similar findings in women.
Uncontrolled diabetes and hypertension can be both a result and a confounder.
Adrenal incidentaloma can produce silent cortisol and should be evaluated separately (relevant protocol).
Adrenocortical carcinoma should be considered in rapidly developing cases accompanied by signs of male hormones.
Adrenal insufficiency that develops in the post-treatment period should be considered as a separate condition (relevant protocol).

Red flags

Proceeding with hormone tests and imaging without investigating EXTERNAL CORTISONE INTAKE → MOST COMMON CAUSE IS MEDICATION GIVEN BY THE PHYSICIAN.
Asking the cortisone question ONLY in the form of TABLETS → INTRA-ARTICULAR, CREAM, RESPIRATORY, NOSE, EYE, and RECTAL routes also produce the same picture, and the patient does not count these as MEDICATION.
Failure to question NEWLY ADDED MEDICATION in a patient using low-dose respiratory corticosteroid → some ANTIFUNGAL and ANTIVIRAL drugs INHIBIT THE DESTRUCTION ENZYME, corticosteroid ACCUMULATES, and conspicuous Cushing's appears; no connection is made because the DOSE HAS NOT CHANGED.
Interpreting screening results as they are in the presence of ALCOHOL, DEPRESSION, UNCONTROLLED DIABETES, and ADVANCED OBESITY → these conditions cause tests to yield FALSE POSITIVE results.
Diagnosis being made or excluded with a SINGLE TEST → usually ABNORMALITY IN TWO DIFFERENT TESTS is sought.
Excluding diagnosis with a SINGLE NORMAL TEST → the condition may be SEASONAL; if clinical suspicion persists, evaluation SHOULD BE REPEATED.
Attributing all findings to OBESITY → the distinctive factor is the COMBINATION OF MUSCLE WASTING IN ARMS AND LEGS WITH TRUNK FAT.
Failure to examine the CHILD'S GROWTH CURVE → the combination of STOPPED HEIGHT GAIN and WEIGHT INCREASE is a strong warning.
Ignoring BLOOD CLOT RISK → these patients have a CLEARLY INCREASED risk of intravascular clotting, especially during SURGERY and IMMOBILITY periods.
Waiting for warning signs like FEVER in infections → since immunity is suppressed, symptoms may remain SUBTLE and diagnosis is delayed.
Not providing GLUCOCORTICOID SUPPORT after the disease is resolved → the body’s own production remains suppressed for MONTHS, sometimes YEARS.
Not giving ADRENAL INSUFFICIENCY EDUCATION to the patient after treatment → disease-day rules, injection, and warning card are also valid for these patients.
Mistaking post-treatment weakness and pain for TREATMENT FAILURE → a body accustomed to high cortisol for years experiences this course while returning to normal; this should be explained to the patient IN ADVANCE.

Disposition and follow-up

Green zone: Patient with detected external corticosteroid use and whose condition is explained by it: reviewing the medication, planning tapering, and providing education regarding adrenal insufficiency.
Yellow zone: Patient with excluded external use and clinical suspicion: performing screening tests after confounding factors are resolved, confirming with two tests, and referring to endocrinology; simultaneous management of complications.
Red zone: Severe hypokalemia, uncontrolled blood sugar, severe signs of infection, psychosis, clot findings or rapidly progressing and accompanied by male hormone findings: urgent evaluation and further center referral. Hypotension and vomiting in the post-treatment period: adrenal crisis should be considered, treatment should not be delayed (protocol involved).

Key clinical points

READ FIRST — the most common cause is the prescribed drug

When you think of Cushing's, a HORMONE-PRODUCING TUMOR comes to mind — HOWEVER, IN DAILY PRACTICE, THE MOST COMMON CAUSE IS CORTISONE-TYPE DRUGS PRESCRIBED BY A PHYSICIAN | THIS DISTINCTION CHANGES THE ENTIRE DIAGNOSTIC PROCESS: IF THERE IS EXTERNAL INTAKE, HORMONE TESTS ARE MISLEADING and UNNECESSARY IMAGING is done | IT IS CRITICAL THAT THE QUESTIONING IS COMPREHENSIVE: WHEN PATIENTS ARE ASKED "DO YOU USE CORTISONE", MOST OF THEM ONLY THINK ABOUT ORAL PILLS and ANSWER NEGATIVELY | OTHER WAYS THAT CAN DO THE SAME PICTURE: INTRA-ARTICULAR INJECTIONS | CREAMS AND OINTMENTS APPLIED TO A LARGE AREA FOR A LONG TIME | SPRAYS used for ASTHMA and ALLERGIC RHINITIS | EYE DROPS | Used through MAKATs | COMMON FEATURES: THEY ARE NOT CONSIDERED A MEDICINE BY PATIENTS — JOINT INJECTION IS PERCEIVED AS A PROCEDURE, CREAM AS A CARE PRODUCT, SPRAY AS A HABITUAL DAILY APPLICATION | RULE: THE QUESTION IS ASKED NOT IN A GENERAL WAY, BUT BY COUNTING THE WAYS OF USE ONE BY ONE

The most common cause of Cushing's syndrome in daily practice is not a hormone-producing tumor, but cortisone-type drugs prescribed by the physician. This distinction changes the entire diagnostic process because if there is external intake, hormone tests are misleading and unnecessary imaging is performed. It is critical that the inquiry is comprehensive; When patients are asked if they use cortisone, most of them only think about pills and answer negatively. However, intra-articular injections, creams applied to a large area, respiratory tract and nasal sprays, eye drops and those used through the anus can also cause the same picture. Since these products are not considered medicines by patients, the question should be asked by counting the ways of use one by one.

SPECIAL TRAP — the dose did not change, but the table came out

ONE OF THE MOST EDUCATIONAL EXAMPLES SHOWING HOW DRUG INTERACTIONS TRANSLATE INTO CLINICAL OUTCOMES | NORMAL SITUATION: the SAFETY of inhaled and nasal corticosteroids depends on the RAPID BREAKDOWN of the ABSORBED AMOUNT in the LIVER → therefore they normally DO NOT PRODUCE EFFECT THROUGHOUT THE BODY | HOWEVER, this breakdown is carried out by a SPECIFIC ENZYME SYSTEM, and there are DRUGS THAT STRONGLY SUPPRESS this system — some ANTIFUNGAL drugs and some ANTIVIRAL drugs are at the forefront | WHEN ONE OF THESE DRUGS IS ADDED: corticosteroid can no longer be BROKEN DOWN RAPIDLY → it ACCUMULATES IN THE BLOOD → starts to show EFFECT THROUGHOUT THE BODY | RESULT: in a patient who has been using a low-dose and CONSIDERED SAFE drug for YEARS, a clear Cushing syndrome appears WITHIN WEEKS | WHAT MAKES IT DIFFICULT TO RECOGNIZE: the patient's CORTISONE DOSE HAS NOT CHANGED → therefore NO CONNECTION IS MADE, and the patient is examined for a HORMONE-PRODUCING TUMOR | RULE: in this scenario, NEWLY STARTED DRUGS should be reviewed.

This scenario is an educational example showing how drug interactions translate into clinical outcomes. The safety of inhaled and nasal corticosteroids depends on the rapid breakdown of the absorbed amount in the liver; this breakdown is carried out by a specific enzyme system. Some antifungal and antiviral drugs strongly suppress this system; when one of these drugs is added, corticosteroids cannot be broken down, accumulate in the blood, and produce effects throughout the body. The result is the emergence of a clear Cushing syndrome within weeks in a patient who has been using a low-dose and considered safe drug for years. What makes recognition difficult is that the patient’s cortisone dose has not changed; no connection is made, and the patient is examined for a tumor.

Situations causing false positives and the two-test rule.

MOST COMMON DIFFICULTY: cortisol production CAN INCREASE DUE TO REASONS OTHER THAN REAL DISEASE | MECHANISM: the body increases cortisol production in response to ONGOING STRESS — this increase is NOT DISEASE, IT IS THE RESULT OF NORMAL SYSTEM FUNCTION | SITUATIONS THAT CAUSE FALSE POSITIVES: ALCOHOL CONSUMPTION | DEPRESSION and ANXIETY DISORDERS | UNCONTROLLED DIABETES | SEVERE OBESITY | PREGNANCY | MEDICATIONS CONTAINING ESTROGEN | IRREGULAR SLEEP PATTERNS and SHIFT WORK | In these patients, screening tests can appear ABNORMAL and the picture may NOT BE DISTINGUISHABLE FROM TRUE CUSHING'S | RULE 1: before screening, these conditions are INQUIRED ABOUT and if POSSIBLE, tests are performed AFTER CORRECTION — results obtained while alcohol consumption persists or diabetes is UNCONTROLLED are NOT RELIABLE | RULE 2: diagnosis is NOT BASED ON A SINGLE TEST — MULTIPLE TESTS can be used and each has its OWN LIMITATIONS → usually, ABNORMAL results from TWO DIFFERENT TESTS are sought, and if results are INCONSISTENT, the evaluation is REPEATED | Choice of test and thresholds SHOULD BE VERIFIED FROM INSTITUTIONAL PROTOCOL

The most common difficulty in screening is that cortisol production can increase due to reasons other than real disease. The body increases cortisol production in response to ongoing stress, and this increase is not disease but a result of normal system function. Alcohol consumption, depression and anxiety disorders, uncontrolled diabetes, severe obesity, pregnancy, medications containing estrogen, and irregular sleep patterns are among these conditions; in these patients, tests may appear abnormal and the picture may not be distinguishable from true Cushing's. Therefore, before screening, these conditions should be inquired about and, if possible, tests should be performed after correction. Also, diagnosis should not be based on a single test; usually, abnormal results from two different tests are sought.

Distinctive finding — what is UNEXPECTED in obesity

MOST OF THE FINDINGS ARE COMMON ALONE: weight gain, fatigue, high blood pressure, high blood sugar, mood changes → THESE ARE ALREADY EXPECTED findings in an OBESE PATIENT | WHAT LEADS TO THE DIAGNOSIS IS NOT THE PRESENCE OF THESE FINDINGS, BUT THE PRESENCE OF UNEXPECTED FINDINGS IN OBESITY | (1) MUSCLE WASTING — THE MOST IMPORTANT: excess cortisol DESTROYS MUSCLE TISSUE → THINNING IN ARMS and LEGS | meanwhile, FAT ACCUMULATION IN THE TRUNK, FACE, and NECK INCREASES | THE PRESENCE OF BOTH FINDINGS IN THE SAME PATIENT cannot be explained by SIMPLE OBESITY | Practical finding: difficulty for the patient to STAND UP FROM A SITTING POSITION (thigh muscles) | (2) SKIN CHANGES: cortisol thins the CONNECTIVE TISSUE UNDER THE SKIN → WIDE and PURPLE STRIAE | EASY BRUISING FROM MINOR TRAUMA | DELAYED WOUND HEALING | THINNING OF THE SKIN | (3) THE STRONGEST CLUE IN CHILDREN IS THE GROWTH CURVE: excess cortisol SUPPRESSES HEIGHT GROWTH WHILE INCREASING WEIGHT → IN A GROWTH-STOPPED BUT WEIGHT-GAINING CHILD, this diagnosis is PRIMARILY considered | PERIODIC COURSE: production may be INTERMITTENT → A SINGLE NORMAL TEST DOES NOT EXCLUDE THE DIAGNOSIS; if suspicion persists, it is REPEATED

Most Cushing findings are common alone and are already expected in an obese patient. What leads to the diagnosis is the simultaneous presence of unexpected findings in obesity. The most important is muscle wasting; cortisol destroys muscle tissue, causing thinning in the arms and legs while fat accumulation increases in the trunk, face, and neck, and this combination cannot be explained by simple obesity. Difficulty for the patient to stand up from a sitting position is a practical finding. Skin changes are also distinctive: wide and purple striae, easy bruising, delayed healing wounds, and thinned skin. In children, the strongest clue is the growth curve; in a child whose height is stagnant but gaining weight, this diagnosis should be primarily considered. Since the pattern may be intermittent, a single normal test does not exclude the diagnosis.

LIFE-THREATENING — the patient may develop insufficiency after treatment

THE MOST FREQUENTLY OVERLOOKED PHASE: period AFTER the disease has been RESOLVED | MECHANISM: in a body exposed to HIGH CORTISOL for a long time, the pituitary's STIMULUS PRODUCTION and the intact adrenal gland tissue are SUPPRESSED | When the source of the disease is ELIMINATED, cortisol levels DROP RAPIDLY — however, the SUPPRESSED SYSTEM CANNOT START WORKING IMMEDIATELY → RECOVERY TAKES MONTHS, SOMETIMES YEARS | DURING THIS INTERIM PERIOD, THE PATIENT IS FUNCTIONALLY IN A STATE OF ADRENAL INSUFFICIENCY and CANNOT SURVIVE WITHOUT EXTERNAL SUPPORT | RULE: these patients receive the FULL TRAINING given to patients with adrenal insufficiency — DISEASE DAY RULES (dose increase) | INTRAMUSCULAR INJECTION IN CASE OF VOMITING | WARNING CARD TO CARRY | SECOND IMPORTANT POINT — DURING THE TRANSITION PERIOD, THE PATIENT FEELS POOR: a body accustomed to HIGH CORTISOL for years experiences FATIGUE, MUSCLE and JOINT PAIN, LOSS OF APPETITE, and MOOD SWINGS as it returns to normal | THIS SITUATION IS NOT A TREATMENT FAILURE — if not explained in advance, the patient THINKS THE TREATMENT WAS INEFFECTIVE | ALSO: in these patients, the RISK OF BLOOD CLOTS IS SIGNIFICANTLY INCREASED (especially during SURGERY and periods of IMMOBILITY) | IN INFECTION, warning signs like FEVER may be DIMMED

The most frequently overlooked phase of treatment is the period after the disease has been resolved. In a body exposed to high cortisol for a long time, the pituitary's stimulus production and the intact adrenal gland tissue are suppressed; when the source is removed, cortisol drops rapidly but the suppressed system cannot function immediately, and recovery takes months, sometimes years. During this interim period, the patient is functionally in a state of adrenal insufficiency. Therefore, full training including disease day rules, intramuscular injection in vomiting, and a warning card must be given. Additionally, during the transition period, the patient experiences fatigue, muscle and joint pain, and mood depression; this situation is not a treatment failure, and if not explained in advance, the patient may think the treatment is ineffective. In these patients, the risk of blood clots is also significantly increased.

Featured external sources

Detailed assessment

Diagnostic and decision reasoning

Clinical framework

Overview

Cushing's syndrome is a condition that occurs when the body is exposed to high levels of cortisol for a long time. The first question to ask during evaluation is not where the hormone comes from, but whether the patient has been taking corticosteroids externally, because the most common cause is medication prescribed by a doctor.

This question is insufficient if asked only about pills; intra-articular injections, skin creams, inhalation and nasal sprays, eye drops, and medications administered rectally can also cause the same picture, and patients do not consider these as medications. A particular trap is when a patient using low-dose inhaled corticosteroids is given a drug that inhibits the liver enzyme responsible for breakdown, leading to the emergence of a noticeable condition; since the corticosteroid dose did not change, no connection is made.

When external intake is excluded, screening is performed, but alcohol use, depression, uncontrolled diabetes, and advanced obesity can cause false-positive test results. Clinical findings leading to diagnosis are unexpected muscle loss and skin changes in obesity; in children, the combination of halted height growth and weight gain is a strong warning sign.

After treatment, the body's own production remains suppressed for a long time, and the patient requires adrenal insufficiency education.

Differential diagnosis and assessment

Key considerations

Intake of corticosteroids from outside is the most common cause and cannot be excluded without investigating all routes of administration.
Pseudo-Cushing states (alcohol, depression, uncontrolled diabetes, advanced obesity) cause false-positive test results.
Metabolic syndrome and obesity create a similar appearance but there is no muscle wasting or purple striae.
Polycystic ovary syndrome can be confused with hirsutism and menstrual irregularities in women.
Adrenal incidentaloma may produce silent cortisol (relevant protocol).
Adrenocortical carcinoma should be considered in rapidly developing cases accompanied by signs of male hormones.
Ectopic hormone-secreting tumors cause a rapidly progressing condition accompanied by marked hypokalemia.
Post-treatment adrenal insufficiency should be considered as a separate condition (relevant protocol).

Clinical decision reasoning

Why it matters

The points that determine clinical outcomes in the management of Cushing's syndrome arise from the fact that the diagnosis can be both over- and under-applied. The first point is to investigate external intake; although this is the most common cause, if the question is asked only about tablets, it remains incomplete, and the patient is examined with unnecessary tests.

The second point is the picture that emerges with enzyme-suppressing drugs; since the corticosteroid dose has not changed, no connection is made, and the patient is evaluated by searching for a tumor. The third point is the limitation of screening tests; cortisol production also increases in ongoing stress, leading to false positives from alcohol, depression, uncontrolled diabetes, and severe obesity.

Therefore, these conditions should be corrected before testing, and the diagnosis should be supported with two different tests. The fourth point is clinical distinction; since most findings are already expected in obesity, the features leading to the diagnosis are the combination of muscle wasting with truncal obesity and skin changes, while in children, the growth chart is the strongest clue.

The fifth point is periodic progression; a single normal test does not exclude the diagnosis. The final and most crucial point is the post-treatment period; as the suppressed system cannot recover for months, the patient functionally has adrenal insufficiency, and if this education is not provided, a preventable crisis can occur.

Safety and monitoring

Complications and safety

Critical complications

High blood sugar and blood pressure are common and require treatment on their own.
Bone density rapidly decreases, and even young patients have a risk of fractures.
As the immune system is suppressed, infections are more frequent and severe, and warning signs remain subtle.
Muscle weakness is particularly notable in the thigh muscles and limits daily life.
Psychiatric effects (insomnia, restlessness, mood swings, depression) impair quality of life.
The risk of intravascular clotting is significantly increased and becomes important during surgery and periods of immobility.
Long-lasting adrenal insufficiency after treatment leads to a crisis if education is not given.
Weakness and pain during the transition period are mistaken for treatment failure, which disrupts adherence to therapy.

Special patient populations

Special considerations

In children, the growth chart is the strongest clue; a child who stops growing in height but gains weight should be primarily considered for diagnosis.
In patients using inhaled corticosteroids and adding enzyme-suppressing drugs, the condition can develop rapidly.
In pregnant women, screening tests should be conducted with expert evaluation because they can give false positive results.
In patients who consume alcohol and have depression, these conditions should be addressed before the test.
Screening in patients with uncontrolled diabetes should be performed after control is achieved.
In patients planned for surgery, clotting risk should be evaluated separately.
Patients in the post-treatment period should be educated like patients with adrenal insufficiency.
In elderly patients, bone loss and infection risk are more pronounced.

Follow-up and reassessment

Follow-up plan

Follow-up in Cushing's syndrome includes two separate periods: before diagnosis and after treatment. Medications used in the diagnostic process should be reviewed at each visit, products containing cortisone should be queried in all forms of use, and it should be assessed whether newly started medications cause interactions.

Screening tests should be performed after confounding conditions are resolved, and if results are inconsistent, the tests should be repeated; if clinical suspicion continues, a single normal test should not be considered sufficient, and the patient should be explained why the test is repeated. Even if the diagnostic process is prolonged, the management of complications should not be postponed; blood sugar, blood pressure, bone density, and psychiatric status should be addressed separately.

Since signs of infection may be subtle, the threshold for suspicion should be kept low. Clotting risk should be evaluated especially during surgery and periods of immobility.

Follow-up after treatment should be intensified; the patient should be educated about adrenal insufficiency, disease-day rules, injection use in case of vomiting, and warning cards should be reviewed at each visit. Glucocorticoid tapering should be performed according to institutional protocol and in a controlled manner, and the patient should be informed that this process may take months or even years.

Fatigue, muscle and joint pain, and mood decline occurring during the transition period should be explained in advance as expected. Long-term follow-up should be maintained to monitor for disease recurrence.